Breaking

Rio Tinto Plans US$1.8 Billion Investment in BS1 Extension, Completes Arcadium Acquisition
Crypto Market Recap: Binance Lands Historic Investment as Bolivia Turns to Crypto
FTC asks to delay Amazon Prime deceptive practices case, citing staffing shortfalls
‘You are there and you are not alive’: the harsh testimony of a deported Venezuelan who spent 15 days in Guantanamo
Israel acknowledges possible forced use of civilians in Gaza military operations, launches investigation
Anteros Advances Critical Mineral Targeting with AI-Assisted 3D Modelling at their Havens Steady VMS Property, Newfoundland
AMERICAN SALARS LITHIUM PORTFOLIO HEDGED AMID TRUMP TARIFF CONCERNS
Nigerian star Patoranking draws on his childhood dreams to help African youth

Facebook
Twitter
Google Plus
Instagram
Pinterest
Vimeo

Investing
Stock
Latest News
Editor’s Pick
Economy
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

By December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Crypto Market Recap: Binance Lands Historic Investment as Bolivia Turns to Crypto

Rio Tinto Plans US$1.8 Billion Investment in BS1 Extension, Completes Arcadium Acquisition

Anteros Advances Critical Mineral Targeting with AI-Assisted 3D Modelling at their Havens Steady VMS Property, Newfoundland

Enter Your Information Below To Receive Latest News, And Articles.
Your name

Your email
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest Posts
Categories
- Economy (714)
- Editor's Pick (359)
- Investing (2,464)
- Latest News (2,457)
- Stock (1,148)
About Rightinvestingway

Disclaimer: Rightinvestingway.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 Rightinvestingway.com

Top

Type above and press Enter to search. Press Esc to cancel.